The FDA granted orphan drug designation to MCD-386CR by Mithridion Inc., of Madison, Wis

SEN0014196 previously gained orphan drug designation from both the FDA and the European Medicines Agency

CytRx Corp., of Los Angeles, said the FDA granted orphan drug designation to its cancer candidate INNO-206...Eleison Pharmaceuticals Inc., of Princeton, N.J., said the European Commission has granted orphan drug designation to the company's lead drug, glufosfamide, for the treatment of pancreatic cancer

Provectus Pharmaceuticals Inc., of Knoxville, Tenn., received orphan drug designation from the FDA for Rose Bengal, the active ingredient in its oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer

KG, of Wuppertal, Germany, announced that AIC246, an inhibitor against human cytomegalovirus (HCMV), currently undergoing Phase IIb testing, has been granted orphan drug designation for the prevention of HCMV disease by the European Commission following the positive opinion released by the Committee for Orphan Medicinal Products of the European Medicines Agency...AstraZeneca plc, of London, reported that the orphan drug vandetanib is now available to U.S

AstraZeneca plc, of London, reported that the orphan drug vandetanib is now available to U.S

AiCuris, of Wuppertal, Germany, announced that AIC246, an inhibitor against human cytomegalovirus (HCMV), currently undergoing Phase IIb testing, has been granted orphan drug designation for the prevention of HCMV disease by the European Commission following the positive opinion released by the Committee for Orphan Medicinal Products of the European Medicines Agency...Nektar Therapeutics Inc., of San Francisco, said its oncology candidate, NKTR-102, received orphan drug status for ovarian cancer

Amira Pharmaceuticals Inc., of San Diego, said its lead LPA1 antagonist, AM152, was granted orphan drug status in idiopathic pulmonary fibrosis

London-based AstraZeneca plc's orphan drug vandetanib received FDA approval for advanced medullary thyroid cancer, the only drug approved for that indication

London-based AstraZeneca plc's orphan drug vandetanib received FDA approval for advanced medullary thyroid cancer, the only drug approved for that indication

America Stem Cell Inc., of Helotes, Texas, reported that the FDA has granted orphan drug status to its ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation

VR496 is a proprietary formulation of dry powder heparin sodium and has European Medicines Agency and FDA Orphan Drug status

The drug received orphan drug designation from the FDA in 2008...orphan drug designation, is the second Oxford product to enter clinical development through an early stage ocular collaboration with Sanofi

The drug received orphan drug designation from the FDA in 2008...orphan drug designation, is the second Oxford product to enter clinical development through an early stage ocular collaboration with Sanofi-Aventis Group, of Paris

The Paris-based company received orphan drug approval for Somatuline Depot in 2007

The program has already been granted orphan drug designation by the FDA

The Paris-based company received orphan drug approval for Somatuline Depot in 2007...The FDA granted Stemline Therapeutics Inc., of New York, orphan drug designation for its lead compound, SL-401, for the treatment of acute myeloid leukemia (AML

The FDA granted orphan drug designation to GO-203-2c, a mucin-1 targeting peptide by Genus Oncology LLC, of Vernon Hills, Ill. Genus is in Phase I trials for GO-203-2c for pancreatic cancer...The European Commission has granted orphan drug designation to tasimelteon, an oral dual melatonin receptor agonist being developed by Vanda Pharmaceuticals Inc., of Rockville, Md

Celsion Corp., of Columbia, Md., said the European Commission granted orphan drug designation for the company's lead compound, ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, for the treatment of primary liver cancer...ThermoDox, which also holds orphan drug designation in the U.S., is being evaluated under a special protocol assessment with the FDA in a 600-patient pivotal Phase III trial, the HEAT study, in patients with nonresectable primary liver cancer